Literature DB >> 12685524

Methylphenidate in treatment of adults with Attention-Deficit/Hyperactivity Disorder.

J Biederman1, T Spencer.   

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) can persist into adulthood with a continuation of the pattern of childhood psychopathology, cognition and functioning. Adult comorbidities include substance use disorders, antisocial personality disorder, anxiety, and depression. Studies have shown that as in children, methylphenidate treatment for adults can lead to a robust, dose-dependent improvement in ADHD symptoms. Future research is needed to evaluate the safety and efficacy of long-term treatment with methylphenidate (MPH).

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12685524     DOI： 10.1177/070674370200601s12

Source DB:  PubMed          Journal:  J Atten Disord        ISSN： 1087-0547            Impact factor:   3.256


  16 in total

1.  Effects of sub-chronic methylphenidate on risk-taking and sociability in zebrafish (Danio rerio).

Authors:  Rebecca G Brenner; Anthony N Oliveri; Walter Sinnott-Armstrong; Edward D Levin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-02-06       Impact factor: 3.000

2.  Persistent behavioral impairment caused by embryonic methylphenidate exposure in zebrafish.

Authors:  Edward D Levin; Damiyon Sledge; Stephanie Roach; Ann Petro; Susan Donerly; Elwood Linney
Journal:  Neurotoxicol Teratol       Date:  2011-07-07       Impact factor: 3.763

3.  Differential association between the norepinephrine transporter gene and ADHD: role of sex and subtype.

Authors:  Sarojini M Sengupta; Natalie Grizenko; Geeta A Thakur; Johanne Bellingham; Rosherrie DeGuzman; Sandra Robinson; Marina TerStepanian; Anna Poloskia; S M Shaheen; Marie-Eve Fortier; Zia Choudhry; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

4.  Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations.

Authors:  Erin S Calipari; Mark J Ferris; James R Melchior; Kristel Bermejo; Ali Salahpour; David C S Roberts; Sara R Jones
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

5.  Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.

Authors:  K S Patrick; A B Straughn; R R Minhinnett; S D Yeatts; A E Herrin; C L DeVane; R Malcolm; G C Janis; J S Markowitz
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

6.  Influence of sensitization on the discriminative stimulus effects of methylphenidate in mice.

Authors:  Robin McGovern; Lauryn Luderman; Kelly Knecht; William C Griffin
Journal:  Behav Pharmacol       Date:  2014-12       Impact factor: 2.293

7.  Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.

Authors:  Natalie L LeVasseur; Hao-Jie Zhu; John S Markowitz; C Lindsay DeVane; Kennerly S Patrick
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-04       Impact factor: 3.205

8.  Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.

Authors:  Walter Ling; Linda Chang; Maureen Hillhouse; Alfonso Ang; Joan Striebel; Jessica Jenkins; Jasmin Hernandez; Mary Olaer; Larissa Mooney; Susan Reed; Erin Fukaya; Shannon Kogachi; Daniel Alicata; Nataliya Holmes; Asher Esagoff
Journal:  Addiction       Date:  2014-07-08       Impact factor: 6.526

9.  Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine.

Authors:  Bethany R Brookshire; Sara R Jones
Journal:  Synapse       Date:  2012-06-13       Impact factor: 2.562

10.  Interactive effects of methylphenidate and alcohol on discrimination, conditioned place preference and motor coordination in C57BL/6J mice.

Authors:  William C Griffin; Robin W McGovern; Guinevere H Bell; Patrick K Randall; Lawrence D Middaugh; Kennerly S Patrick
Journal:  Psychopharmacology (Berl)       Date:  2012-09-07       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.